Menu Search
Equities

Johnson & Johnson

JNJ:NYQ

Johnson & Johnson

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)155.50
  • Today's Change2.39 / 1.56%
  • Shares traded10.14m
  • 1 Year change+2.90%
  • Beta0.5054
Data delayed at least 15 minutes, as of Nov 22 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
  • 15-Nov-24
Select bar for recommendation details.
Recommendations15-Nov-24
Buy5
Outperform9
Hold12
Sell0
Strong Sell0

Share price forecast in USD

The 24 analysts offering 12 month price targets for Johnson & Johnson have a median target of 176.55, with a high estimate of 215.00 and a low estimate of 155.00. The median estimate represents a 15.31% increase from the last price of 153.11.
High40.4%215.00
Med15.3%176.55
Low1.2%155.00

Dividends in USD

In 2023, Johnson & Johnson reported a dividend of 4.70 USD, which represents a 5.62% increase over last year. The 5 analysts covering the company expect dividends of 4.57 USD for the upcoming fiscal year, a decrease of 2.79%.
Div growth (TTM)5.62%
More ▼

Earnings history & estimates in USD

On Oct 15, 2024, Johnson & Johnson reported 3rd quarter 2024 earnings of 2.42 per share. This result exceeded the 2.21 consensus of the 14 analysts covering the company and under-performed last year's 3rd quarter results by 9.02%.
The next earnings announcement is expected on Jan 22, 2025.
Average growth rate-1.42%
Johnson & Johnson reported annual 2023 earnings of 9.92 per share on Jan 23, 2024.
Average growth rate+4.19%
More ▼

Revenue history & estimates in USD

Johnson & Johnson had 3rd quarter 2024 revenues of 22.47bn. This bettered the 22.16bn consensus of the 13 analysts covering the company. This was 7.55% above the prior year's 3rd quarter results.
Average growth rate+1.31%
Johnson & Johnson had revenues for the full year 2023 of 85.16bn. This was 6.46% above the prior year's results.
Average growth rate+1.49%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.